New pediatric tumor identifications could help predict chemo response

New pediatric tumor identifications could help predict chemo response
Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. a) Flowchart of tissue processing of HB tumor and adjacent paired normal tissue samples for single-cell RNA sequencing and patient-derived spheroid culture. b) Uniform manifold approximation and projection (UMAP) of 29,968 cells from nine HB patients, annotated by cell types. c) Dot plot of all identified populations, each characterized by three known cell type markers. Average expression was indicated by the color gradient, and the percentage of marker expressed was represented by the dot size. d) Stacked bar charts showing the contribution of the two sample types (normal and tumor) to each cell population, ranked by the contribution from normal samples. e) Estimated copy-number alteration profile of all tumor and tumor-associated cell clusters using all the non-tumor and non-tumor-associated cells as reference. Chromosomes are labeled on the horizontal axis. Estimated copy numbers are shown in blue (deletion) and red (amplification) color bars. f) Stacked bar charts show the contribution of the nine patients to each cell population. Credit: Nature Communications DOI: 10.1038/s41467-022-32473-z

A new UCSF study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment.

The study, published in Nature Communications, used single-cell transcriptomic techniques to analyze hepatoblastoma specimens from infants and children under age four. From nine samples, the researchers identified five hepatoblastoma signatures that may account for the heterogeneity in this cancer, and that may predict responses to chemotherapy treatments.

"Many pediatric tumors originate from an embryonic cell and some are bland in terms of their mutational burden," said study co-author Amar Nijagal, assistant professor in the Division of Pediatric Surgery at UCSF Benioff Children's Hospital, San Francisco. "The fact that this tumor has significant heterogeneity made us question what was driving this heterogeneity, and we wanted to learn more."

Researchers from three different labs at UCSF worked on the study, combining expertise in pediatric surgery, hepatology, and genomics, which facilitated the rare opportunity to analyze tumors directly from the , Nijagal said.

"With this combined expertise in one place at UCSF, we can foresee a situation in which a child presents with a liver tumor; we biopsy it; we understand its tumor signatures; we grow and test therapeutics in a ; and we use what we find to treat the patient," Nijagal said.

Aside from offering hope for better treatment, studying hepatoblastoma provides a window into how tissues develop normally, Nijagal said.

"Normal development and cancer are two sides of the same coin," Nijagal said. "Here you have a tumor that is not acquired, as many adult tumors are from something like smoking or excess UV exposure. Instead, something goes wrong during development to set off these hepatoblasts towards developing into a malignancy. So we are interested in learning what are the signals—such as those from —that maintain ."

More information: Hanbing Song et al, Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids, Nature Communications (2022). DOI: 10.1038/s41467-022-32473-z

Journal information: Nature Communications
Citation: New pediatric tumor identifications could help predict chemo response (2022, August 25) retrieved 26 April 2024 from https://medicalxpress.com/news/2022-08-pediatric-tumor-identifications-chemo-response.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

A new approach for detecting tumor heterogeneity to assess breast cancer patient outcomes

44 shares

Feedback to editors